EGFR and neoplasm: In November 2015, osimertinib received US Food and Drug Administration (FDA) approval for EGFR–TKI-pretreated metastatic EGFRT790M-positive NSCLC, as did the companion diagnostic test (cobas® EGFR Mutation Test v2) that is used to detect tumor EGFRT790M.